Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Tricuspid valve stenosis is a type of heart valve problem. It results from a narrowing of the opening of the tricuspid valve. This valve separates the right atrium and the right ventricle of the ...

Although heart valve problems are more common with age — an estimated 12.4% of Americans older than 75 years have aortic stenosis — structural heart problems can also occur during embryonic ...

The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

Ottawa knocked off Toronto Metropolitan University, an OUA finalist that counted former Wolves captain Liam Ross among its ...

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, ...

They were compared with a group of 56 athletes with a normal tricuspid valve (TAV). Results BAV athletes showed ... In one subject, regurgitation was combined with valvular stenosis, with a maximum ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR ...